Cargando…

Pronounce expression of Tim-3 and CD39 but not PD1 defines CD8 T cells in critical Covid-19 patients

BACKGROUND: During viral infection, inhibitory receptors play a key role in regulating CD8 T-cell activity. The objective of this research was to investigate programmed cell death protein 1 (PD-1), T-cell immunoglobulin and mucin domain-containing protein-3 (TIM-3), and CD39 exhaustion markers in CD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shahbazi, Mehdi, Moulana, Zahra, Sepidarkish, Mahdi, Bagherzadeh, Mojgan, Rezanejad, Maryam, Mirzakhani, Mohammad, Jafari, Mohammad, Mohammadnia-Afrouzi, Mousa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857983/ https://www.ncbi.nlm.nih.gov/pubmed/33548481 http://dx.doi.org/10.1016/j.micpath.2021.104779

Ejemplares similares

Increased Levels of serum Pentraxin 3 in Critical Coronavirus Disease-2019 Patients
por: Moulana, Zahra, et al.
Publicado: (2021)

TIM‐3 as a potential exhaustion marker in CD4(+) T cells of COVID‐19 patients
por: Modabber, Zahra, et al.
Publicado: (2021)

Soluble CD30, the Immune Response, and Acute Rejection in Human Kidney Transplantation: A Systematic Review and Meta-Analysis
por: Mirzakhani, Mohammad, et al.
Publicado: (2020)

Female Unexplained Infertility: A Disease with Imbalanced Adaptive Immunity
por: Ehsani, Motahareh, et al.
Publicado: (2019)

Editorial: The Spectrum of Treg Subsets in Transplantation: Immune Regulation and Tolerance Induction
por: Mohammadnia-Afrouzi, Mousa, et al.
Publicado: (2022)

The association of decreased HLA-G(+) immune cell frequencies with critical COVID-19 patients
por: Ramzannezhad, Somayeh, et al.
Publicado: (2022)

Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer
por: Weimer, Pauline, et al.
Publicado: (2022)

Seroprevalence Estimates of Latent and Acute Toxoplasma Infections in HIV(+) People—Call for Action in Underprivileged Communities
por: Rostami, Ali, et al.
Publicado: (2021)

Characterization of age‐associated exhausted CD8(+) T cells defined by increased expression of Tim‐3 and PD‐1
por: Lee, Kyoo‐A, et al.
Publicado: (2016)

Epithelial ovarian cancer is infiltrated by activated effector T cells co-expressing CD39, PD-1, TIM-3, CD137 and interacting with cancer cells and myeloid cells
por: Tassi, Elena, et al.
Publicado: (2023)

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
por: Brauneck, Franziska, et al.
Publicado: (2021)

Vitamin D receptor expression in sperm of males with unexplained infertility
por: Akbari Sagheb, Zahra, et al.
Publicado: (2023)

PD-1 and Tim-3 Pathways Regulate CD8(+) T Cells Function in Atherosclerosis
por: Qiu, Ming-Ke, et al.
Publicado: (2015)

CD39(+)PD-1(+)CD8(+) T cells mediate metastatic dormancy in breast cancer
por: Tallón de Lara, Paulino, et al.
Publicado: (2021)

Tissue-resident macrophages in the intestine are long lived and defined by Tim-4 and CD4 expression
por: Shaw, Tovah N., et al.
Publicado: (2018)

PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1(hi)CD39(+) CD4 T cells
por: Balança, Camille-Charlotte, et al.
Publicado: (2021)

Tim-3 and PD-1 regulate CD8(+) T cell function to maintain early pregnancy in mice
por: XU, Yuan-Yuan, et al.
Publicado: (2017)

Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73(-) Phenotype Identifies Polyfunctional Cytotoxic Lymphocytes
por: Ahmadi, Parimah, et al.
Publicado: (2020)

Splenic CD4(+) and CD8(+) T-cells highly expressed PD-1 and Tim-3 in cirrhotic patients with HCV infection and portal hypertension
por: Huang, Na, et al.
Publicado: (2021)

Posttreatment Downregulation of Type III Interferons in Patients with Acute Brucellosis
por: Shokri, Mehran, et al.
Publicado: (2021)

Circulating Exhausted PD-1(+)CD39(+) Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade
por: Martinez-Gomez, Carlos, et al.
Publicado: (2022)

Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase Inhibitors
por: Schäkel, Laura, et al.
Publicado: (2020)

Inhibition of Exosome Release Sensitizes U937 Cells to PEGylated Liposomal Doxorubicin
por: Hekmatirad, Shirin, et al.
Publicado: (2021)

‘Elective caesarean section at 38–39 weeks gestation compared to > 39 weeks on neonatal outcomes: a prospective cohort study
por: Pirjani, Reihaneh, et al.
Publicado: (2018)

CD39 Regulation and Functions in T Cells
por: Timperi, Eleonora, et al.
Publicado: (2021)

PD-1 and Tim-3 pathways are associated with regulatory CD8(+) T-cell function in decidua and maintenance of normal pregnancy
por: Wang, S-C, et al.
Publicado: (2015)

CD39/Adenosine Pathway Is Involved in AIDS Progression
por: Nikolova, Maria, et al.
Publicado: (2011)

MDSC subtypes and CD39 expression on CD8(+) T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC
por: Koh, Jiae, et al.
Publicado: (2020)

Inhibitory Molecules PD-1, CD73 and CD39 Are Expressed by CD8(+) T Cells in a Tissue-Dependent Manner and Can Inhibit T Cell Responses to Stimulation
por: Smith, Corinne J., et al.
Publicado: (2021)

CD39 Expression Identifies Terminally Exhausted CD8(+) T Cells
por: Gupta, Prakash K., et al.
Publicado: (2015)

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8(+) T cell dysfunction in melanoma patients
por: Fourcade, Julien, et al.
Publicado: (2010)

The Binding Properties of Glycosylated and Non-Glycosylated Tim-3 Molecules on CD4(+)CD25(+) T Cells
por: Lee, Mi Jin, et al.
Publicado: (2009)

CD39 and control of cellular immune responses
por: Dwyer, Karen M., et al.
Publicado: (2007)

Single-cell profiling defines the prognostic benefit of CD39(high) tissue resident memory CD8+ T cells in luminal-like breast cancer
por: Losurdo, Agnese, et al.
Publicado: (2021)

Low expression of CD39 and CD73 genes in centenarians compared with octogenarians
por: Crooke, Almudena, et al.
Publicado: (2017)

Monitoring and characterizing soluble and membrane-bound ectonucleotidases CD73 and CD39
por: Goueli, Said A., et al.
Publicado: (2019)

CD39 and CD73 as Promising Therapeutic Targets: What Could Be the Limitations?
por: Battastini, Ana Maria Oliveira, et al.
Publicado: (2021)

CD39/CD73/A2AR pathway and cancer immunotherapy
por: Xia, Chenglai, et al.
Publicado: (2023)

The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy
por: Jiang, Xuan, et al.
Publicado: (2023)

Exploring CD39 and CD73 Expression as Potential Biomarkers in Prostate Cancer
por: Gardani, Carla Fernanda Furtado, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bdpe45reiak6koginq35v415tf